Request an appointment

+90 553 851 73 11 · info@luegroup.com.tr

Oncology Code: 46111

EndoPredict®

EndoPredict® is a second-generation gene expression test used in ER-positive, HER2-negative early-stage breast cancer. It combines a 12-gene molecular score with tumour size and lymph node status to calculate the EPclin risk score, answering three clinical questions in a single test.

EndoPredict®
Sample
Paraffin-embedded tumour tissue (FFPE)
Turnaround time
About 1 week
Method
RT-PCR gene expression
Ordering
Following physician assessment
The test is performed on tumour tissue obtained from biopsy or surgical material; it is not a sample the patient can bring in themselves. We plan the process together with your oncologist.

Who is it for?

  • ER-positive, HER2-negative invasive primary breast cancer
  • 0–3 positive lymph nodes, tumour size pT1–3, grade G1–3
  • Pre- or postmenopausal patients
  • Cases where the chemotherapy decision is unclear based on clinical factors

What is in your report?

Three clinical questions in a single test

Can chemotherapy be avoided? (10-year risk of distant recurrence)What is the absolute benefit of chemotherapy?Can endocrine therapy be stopped after 5 years? (risk of late recurrence at 5–15 years)

Genes analysed

12 genes

8 target genes (BIRC5, UBE2C, DHCR7, RBBP8, IL6ST, AZGP1, MGP, STC2), 3 normalisation genes (CALM2, OAZ1, RPL37A) and 1 control gene (HBB).

BIRC5UBE2CDHCR7RBBP8IL6STAZGP1MGPSTC2CALM2OAZ1RPL37AHBB

Technical details

Method
Gene expression (RNA) by RT-PCR
Sample
10 µm sections from FFPE tumour tissue; tumour content of at least 30%; prior to systemic treatment
Turnaround time
Usually within 1 week
Scores
12-gene molecular score (0–15) and EPclin risk score (1–6); the 3.3287 cut-off corresponds to a 10% risk of distant recurrence at 10 years
Evidence
Validated in 4 prospective-retrospective studies (ABCSG-6, ABCSG-8, GEICAM/9906, TransATAC); included in the NCCN, ASCO, ESMO and St. Gallen guidelines
Manufacturer
Myriad Genetics — CE-IVD marked in Europe

Included with your report

  • EPclin score and low / high risk category
  • Probability of distant recurrence at 0–10 years (with endocrine therapy alone)
  • 10-year absolute benefit of chemotherapy
  • Probability of late distant recurrence at 5–15 years

How does the process work?

  1. 1
    Leave your request

    Choose the test, or let your physician request it on your behalf. If you are not sure which test fits, we decide together.

  2. 2
    We call you

    Our team calls within 1 working day to confirm the request, the sample type (blood or tumour tissue) and your appointment time.

  3. 3
    Sample collection

    A blood sample is taken at Akasya Partner Clinics in a few minutes. For tissue tests, the pathology block is collected by courier.

  4. 4
    Report and review

    The report is ready in 1–6 weeks depending on the test (stated on each test page), sent to your physician and reviewed with our consultant physicians.

Last updated:

Your genes are ready to talk.

Send us your request; we will call you, answer your questions and find the day that suits you best, together.

Request an appointment